Rapid advances in our ability to localize and quantify macromolecular changes in health and disease are being brought about by the availability of genetically altered animals (mutants), purified reagents such as monoclonal antibodies, and new molecular methods. Targeted gene deletion (knockouts) and gene insertions (transgenics) in animals can allow identification of the importance and function of macromolecules. Monoclonal antibodies and fluorescent labels coupled with advances in microscopy provide exacting and multidimensional information about localization and cellular changes in proteins, carbohydrates, and lipids using immunohistochemistry, fluorescent activated cell sorting, and immunoprecipitation. Similarly, new applications of molecular methods can be used to identify and localize nucleic acids in tissues via in situ hybridization, polymerase chain reaction (PCR), reverse transcription (RT) PCR, differential display RT-PCR, RNase protection assays, and microchip arrays. The ligand for CD40 (CD40L), an important immunoregulatory molecule, is an example of the successful application of mutants, monoclonal antibodies, and molecular methods to cloning and biological characterization of new molecules. CD40L knockout mice, monoclonal antibodies, and several molecular methods were used to identify mutations in CD40L as the genetic basis for hyper-IgM syndrome in humans, to provide new insights into the pathobiology of Pneumocystis carinii infection, and to evaluate CD40L for immunotherapy of tumors and opportunistic infections.
INTRODUCTION
The discipline of veterinary pathology is undergoing a revolution in knowledge base and skill requirements. As we approach the next millennium, veterinary pathologists will require a heightened familiarity with the manipulation of the genome, advanced biochemistry and immunobiology, computer imaging, and methodologies to identify and characterize subcellular pathophysiology. With the near completion of the entire human genome sequence, the focus of biopharmaceutical research has turned toward systematic and high-throughput methods that isolate altered genes and gene products in disease. As Virchow identified the need to study cells rather than humors for identification of the causes of disease (52), today's pathologist can study expression of intracellular macromolecules as the basis of disease and injury. Cause and effect relationships of disease are no longer dependent on keen observation and gathering evidence over a period that may span a decade or more. Intentional alteration of a single amino acid or gene allows us to identify and characterize protein and cell function at an exponential rate.
Genetic manipulations used in conjunction with better reagents, methods, and tools that localize and quantify macromolecules will continue to enhance our ability to quickly evaluate and understand the pathophysiologic mechanisms that underlie disease and injury. An understanding of the strengths and limitations or potential pitfalls of each technique will allow allocation of resources in the most efficient and productive manner. Miniaturization and high-throughput methods that complement and replace the time-consuming and low-throughput methods of traditional slide-based histopathology should find new utility in investigative pathology. The classical research tools used by pathologists can now be routinely supplemented and enhanced by the availability of genetically engineered animals, confocal microscopy, new and improved labels, and application of new molecular methods to characterize changes in macromolecules (nucleic acids, proteins, lipids, and carbohydrates) and to investigate mechanisms of disease.
In Toxicologic Pathology between 1993 and mid-1998, immunohistochemical techniques were used in 15-27% of the studies published each year as a supplement to light and electron microscopic or morphometric evaluations. A similar utilization of immunohistochemistry and limited use of genetically altered animals or molecular methods was reported in Veterinary Pathology during the same period (data not shown). Clearly, immunohistochemistry is the favored and most widely used investigative tool in pathology, whereas genetically altered animals and molecular methods appear to be underutilized.
We focus here on recent improvements and examples of problem areas and practical uses for genetically altered mice, immunohistochemistry, and slide-based molecular methods that are available to pathologists for investigating mechanisms of disease and injury.
MUTANTS, MONOCLONAL ANTIBODIES, AND

MOLECULAR METHODS
Mutants
Until the early 1980s, animal models of human disease were restricted to the sporadic occurrence of spontaneous mutations or the chemical and physical alteration of nor-mal animals (4) . Conversely, the more recently adopted purposeful gene transfer into (transgenics) and targeted gene deletion from (knockouts) mouse embryos have provided specific mutations nearly on demand (16, 17) . Knockout and transgenic animals provide an in vivo system and cells for in vitro assays to evaluate the phenotypic consequences of gene underexpression and overexpression, respectively, on macromolecular function and regulation. Despite the cost of production, genetically altered mice are now often routinely generated as part of discovery and development programs for new biologics. Additionally, mice lacking or transgenic for specific oncogenes or DNA repair genes (XPA) or lacking the p53 tumor suppressor gene are being evaluated as alternatives to expedite traditional 2-yr carcinogenicity bioassays and to evaluate the genotoxic potential of chemicals (11) . Mutations are also generated in tandem, and founder lines are crossed with spontaneous mutations to produce double or triple mutations for experimental manipulation. Mutations generally involve multiple organs, but tissuespecific mutations can be generated with promoters that result in localized tissue oversecretion of molecules (e.g., lung-specific mutations generated with surfactant promoter). Conditional mutations, those that are regulated by molecular triggers, may have far reaching implications for investigative and toxicologic pathology (44) . A change in genetic background may modify viability and expression of the phenotype (23, 28) . Alterations that may result from induced mutations include lethality, diffuse or localized developmental defects, unique metabolic or regulatory defects, recapitulation of spontaneous mutations, hyperplasia, and neoplasia (16, 17, 25, 32, 49, 51) . These outcomes have helped to define biological processes by highlighting the singular importance, overlapping functions, and absolute redundancy of molecules involved in regulation of complex biological processes, such as inflammation.
Tumor necrosis factor (TNF), an important proinflammatory cytokine with 2 cellular receptors, TNFRp55 and TNFRp75, provides an interesting model for investigating immunoregulatory function and mechanisms of injury. Individually and in combination, TNF receptors have been deleted from mice and the resulting progeny used to investigate the complexities of septic shock and inflammation (19, 35, 39, 48) , atherosclerosis, (41), brain injury, (7) and hepatotoxicity (21, 40, 56) . TNFR signalling contributes to hepatotoxicity of N-nitrosodimethylamine, with TNFRp55 specifically mediating the early and necrotic lesions, whereas TNFRp75 mediates cellular infiltrates into the liver (35, 40) . Similarly, mice deficient for TNFRp55 but not TNFRp75 have reduced NFK-B, STAT3 binding, and interleukin (IL)-6, increased TNF, and impaired hepatocellular mitogenic responses after carbon tetrachloride exposure. Hepatocellular regeneration is restored by pretreatment with IL-6 (56). This ability to separate or uncouple the events of cellular infiltration from cellular death (22, 40) has important implications for investigating toxic injury and immunotoxicity (26) .
Monoclonal Antibodies
The study of protein, carbohydrate, and lipid function and expression, identification of targets for biologics, and investigation of mechanistic pathways are often accomplised through use of antibodies. Monoclonal antibodies, and less frequently polyclonal antibodies, identify and specifically localize target molecules in cell suspensions ex vivo and in vitro and in situ within cells and tissues. Monoclonal antibodies also block molecules and their receptors, which has led to targeted therapies against cancer and infections (29, 51) . Antibodies used in immunohistochemistry, enzyme-linked immunosorbent assays, flow cytometry, and fluorescent activated cell sorting are combined with molecular methods (e.g., in situ hybridization) to provide valuable correlations between mRNA and protein expression. However, changes in mRNA activity do not necessarily correlate with changes in protein secretion. Sensitivity, specificity, and availability of reagents often dictate the feasibility of preferentially investigating proteins or other macromolecules over nucleic acids.
Despite the general acceptance of immunohistochemistry for in situ identification and localization of macromolecules, particularly proteins, care must still be exercised in optimization of protocols and interpretation of results. Protocols with insufficient and false characterization of antibodies, lack of reproducibility and appropriate controls, and biologically irrelevant staining are still frequently reported. Irrespective of label or detection system, the appropriate use of controls is required for valid interpretation. Reliance on minimalistic specificity information typically found in publications or vendor databases should be avoided. Rigorous confirmation of crossspecies reactivity using procedural and biological controls, including absorption controls, is critical to valid interpretation of immunohistochemistry results. Many controls are possible, but until quality staining (i.e., specific staining with minimal to no background staining) can be demonstrated, quality and validity of the staining results must be questioned. In some cases, biological negative or positive controls may not be available, but tissues from genetically altered mice and continuous cell lines or transfected cells grown on or centrifuged onto slides are valuable controls.
Loss or masking of antigens due to fixation and paraffin embedment has been partially compensated for by antigen unmasking or retrieval protocols (enzymatic digestion, steam, microwave, and special buffers) or increasing permeability with detergents or saponin. These additional steps often increase background and false-positive staining. Furthermore, optimization of all steps of the staining protocol should be performed to eliminate excess reagents and incubations, particularly if a semiquantitative evaluation is envisioned (24) . Indirect immunohistochemical protocols are most commonly used, but direct labeling of the primary antibody is useful for eliminating nonspecific staining, particularly if the antibody and test tissues originate from the same species. Recent advances in detection systems include tyramide conjugates as substrates for horseradish peroxidase and fluorochromes (50) . Abbreviations: FACS = fluorescence activating cell sorting; ELISA = enzyme-linked immunosorbent assay; ISH = in situ hybridization; RFLP = restriction fragment length polymorphism; PCR = polymerase chain reaction; RT-PCR = reverse transcriptase PCR; DDRT-PCR = differential display RT-PCR.
In recent years, fluorescent probes have gained renewed acceptance because of better fluorochromes, detection systems, and improvements in conventional fluorescent microscopy. Confocal microscopy permits visualization of multiple fluorochromes, digital alteration of signal-to-background ratio, and singleor multidimensional reconstructions of living cells and tissues. The bioluminescent green fluorescent protein (GFP) is also gaining acceptance because it is incorporated into foreign genes and can be used as a marker of gene expression, protein localization, and protein dynamics (33) . Recombinant microorganisms (viruses, bacteria, fungi, and parasites) and other fusion proteins expressing GFP can be used to track infectious diseases, tumors, and macromolecules and for drug screening (10, 33) . Nearly all cells from GFP transgenic &dquo;green&dquo; mice are labeled, and ultraviolet light can be used to readily identify pups positive for insertions and to visualize tissues transplanted from these mice to recipients (36) .
Molecular Methods
Changes in expression of genes and their products underlie disease and injury. A variety of molecular biological methods can be applied to fresh and fixed tissues to evaluate the role of RNA and DNA in disease. Table I summarizes common molecular tools that are useful in evaluating RNA and DNA and contrasts them with methods that identify other macromolecules, particularly proteins. Immunohistochemistry, western blots, or other methods used to identify proteins or other gene products are complemented by using molecular biological tools such as in situ hybridization or solution polymerase chain reaction (PCR) or reverse transcriptase (RT) PCR. In most cases, biological relevance of macromolecular changes is best evaluated by combining 1 or more methods that measure changes in gene function and expression of gene products. The method of choice depends on types and availability of tissues and reagents, expertise of the researcher, need for quantification, and the information already available. Molecular biological methods can be slide or solution based and can be used to investigate single or multiple nucleic acids. Except for in situ hybridization and microdissection, molecular methods are generally not useful for tissue localization, but they offer advantages in semiquantification, greater throughput, and no need for paraffin embedment and sectioning.
For the pathologist, it may be useful to separate molecular methods into those that work with whole tissues, groups of cells, or single cells. Whole fresh tissue can be used to prepare extracts of both DNA and mRNA for PCR and RT-PCR, respectively (8, 15, 27, 53, 57) . Differential display RT-PCR is gaining some acceptance as a technique for comparing mRNA activity in normal or diseased tissues and identifying alterations in genes or identifying rare, differentially expressed genes (3, 22) . Alternatively, RNase protection assays evaluate multiple mRNAs in tissues without amplification of target or signal (38) . Groups of cells are obtained from selective microdissection of fresh tissue, whole paraffin-embedded blocks, or routinely prepared slides (9, 13, 14, 31, 34, 58) . DNA, and to a lesser extent mRNA, can be extracted, purified, and identified in routinely prepared tissues.
Localization of nucleic acid changes and examination of single cells requires in situ hybridization, using oligonucleotide probes or riboprobes on formalinor paraformaldehyde-fixed tissue sections (5, 6, 13, 47) . Typically, specificity of the probe is determined by comparison of sense and antisense probes and of biological negative and positive tissues to evaluate signal-to-background ratios. However, absence of staining using a sense probe is not a guarantee of specificity. It is useful to evaluate several probes directed against different molecules on the same tissue to determine if nonspecific binding of the probe or detection system is responsible for background staining. Biological negative control tissues can be prepared by digestion of tissue sections with DNase or RNase, but additional incubations may substantively alter morphology of tissues and increase background staining. Tissues prepared from knockout animals also do not provide an adequate biological negative control unless the entire probe sequence lies within the area of the gene deletion. Differences in optimization requirements for test molecules and housekeeping genes (e.g., ~-actin), differences in tissue optimization, poor quality tissue preparation, and poor technique add to difficulties in utilizing in situ hybridization. Despite the time-consuming nature and technical difficulty involved, in situ PCR has been used to identify and amplify rare copies of DNA in tissue sections (37) . Similarly, in situ RT-PCR has been described for mRNA in tissues, but this technique lacks reproducibility in most applications.
High-throughput screening is also becoming an important analytical tool in biotechnology. Gene chips consist of a template of thousands of unique genes on slides (gene microarrays) that can be simultaneously analyzed. Changes in genes and gene activity can be identified through binding of probes that mark normal and diseased tissues. Analysis requires automated evaluation for the presence of and differential expression of fluorescent signals (20) . Expressed sequence tags (ESTs) are useful for identifying new members of macromolecular families with clinical utility (55) and can be used as part of a high-throughput technique to evaluate mechanisms of disease. Gene chips and ESTs in combination with immunohistochemistry and in situ hybridization help to identify a variety of altered genes and putative new targets for biopharmaceuticals and to evaluate tissues and cell binding of novel biopharmaceuticals (59) . DISCOVERY AND BIOLOGY OF CD40L: UTILIZATION OF MUTANTS, MONOCLONAL ANTIBODIES, AND MOLECULAR METHODS CD40 ligand (CD40L), a member of the TNFR superfamily, provides a prime example of the successful application of mutants, monoclonal antibodies, and molecular methods to identify immunoregulatory molecules and the genetic basis of a disease and to characterize biological function, tumor immunobiology, and pathogenesis of opportunistic infections. Murine CD40L was cloned by isolating cells that bound to its receptor, CD40.
RNA extracted from these cells were used to make a cDNA library and to select the single cDNA that bound CD40 (2, 46) . Cells and tissues were probed using northern blots to identify in vivo CD40L expression in CD4+ + T lymphocytes, B cells, and dendritic and endothelial cells (12, 30, 45, 46) . Using transfected cell lines, CD40L was shown to be mitogenic for purified human tonsillar B cells, to induce IgE secretion from IL-4-stimulated B cells (2) , and to be a required signal for Tand B-cell interactions in development of thymic-dependent immunity (30, 46) . Subsequently, CD40 expression was identified on malignant lymphomas, indicating a potential role for this molecule in tumor immunotherapy. Furthermore, cytokine release has been associated with activated cells in lymphomas and may account for some clinical para-neoplastic symptoms associated with these tumors (18) . Immunex generated a soluble recombinant trimeric form of CD40L that has been used for successful experimental tumor immunotherapy in mice, and a phase I clinical trial for tumor immunotherapy using CD40L is currently underway.
X-linked hyper-IgM syndrome is an immunodeficiency syndrome in humans, with Band T-cell defects expressed as a lack of immunoglobulin and isotype switching, and numerous opportunistic infections, respectively. Lymphocytes from patients with X-linked hyper-IgM syndrome analyzed by RT-PCR for CD40L showed changes in expression of CD40L or ability to bind CD40, identifying the genetic basis for this immunodeficiency disorder (1) . Generation of mice deficient for CD40L showed similar defects in T-and B-cells, providing a new genetically appropriate animal model of a human immunodeficiency disease. These deficient mice develop spontaneous infections with the fungus Pneumocystis carinii (43) . Other investigators have shown that CD40L is required for resolution of P. carinii infection in vivo, and CD40L is blocked by cyclosporine and steroids in vitro (54) , which are treatments associated with acquired immunodeficiency and spontaneous pneumocystosis. Recombinant soluble CD40L enhances resolution of P. carinii infection in CD40L-deficient mice with spontaneous and induced infections (42, 43) . Using a commercially available antibody to P. carinii, fluorescent activated cell sorting has been used to count fungal asci to provide accurate and consistent experimental infections of CD40L-deficient, C57BL/6, CB.Y 17 SCID, and dexamethasone-immunosuppressed mice. This antibody and PCR have also been used to identify subclinical infections with P. carinii in lungs and blood of immunodeficient and immunologically normal mice (W. C. Fanslow and K. A. Harrington, unpublished data). Immunohistochemistry and RT-PCR have been used to characterize cellular and cytokine responses during infection (Schuh and Harrington, unpublished data). Failure of amphotericin B, antiparasitic, and antimicrobial agents to eradicate P. carinii and recently identified resistance to aerosolized pentamidine underscores the growing importance of pursuing immunotherapy using CD40L as a targeted and biologically relevant treatment for P. carinii pneumonia.
